-
1.发明申请HUMAN ANTI-IFN-GAMMA NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-GAMMA PATHWAY INHIBITORS 有权人类抗IFN-GAMMA作为选择性IFN-GAMMA途径抑制剂中和抗体公开(公告)号：US20080107655A1
公开(公告)日：2008-05-08
申请号：US11962594
申请日：2007-12-21
申请人： Andrew Welcher , Hilary Chute , Yue-Sheng Li , Haichun Huang
发明人： Andrew Welcher , Hilary Chute , Yue-Sheng Li , Haichun Huang
IPC分类号： A61K39/395 , C07K16/18 , A61P25/00 , A61P1/00
CPC分类号： C07K16/249 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76
摘要： This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-γ) and methods for treating IFN-γ mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-γ. Methods of detecting the amount of IFN-γ in a sample using antibodies to IFN-γ are also provided.
摘要翻译： 本发明提供了与人类干扰素-γ（IFN-γ）相互作用或与之结合的抗体以及通过向IFN-γ施用药学上有效量的抗体来治疗IFN-γ介导的疾病的方法。 还提供了使用针对IFN-γ的抗体检测样品中IFN-γ量的方法。
-
2.发明申请Human anti-IFN-gamma neutralizing antibodies as selective IFN-gamma pathway inhibitors 有权人抗IFN-γ中和抗体作为选择性IFN-γ途径抑制剂公开(公告)号：US20050004353A1
公开(公告)日：2005-01-06
申请号：US10684957
申请日：2003-10-14
CPC分类号： C07K16/249 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76
摘要： This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-γ) and methods for treating IFN-γ mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-γ. Methods of detecting the amount of IFN-γ in a sample using antibodies to IFN-γ are also provided.
摘要翻译： 本发明提供了与人类干扰素-γ（IFN-γ）相互作用或与之结合的抗体以及通过向IFN-γ施用药学上有效量的抗体来治疗IFN-γ介导的疾病的方法。 还提供了使用针对IFN-γ的抗体检测样品中IFN-γ量的方法。
-
3.发明申请Human Anti-IFN-gamma Neutralizing Antibodies as Selective IFN-gamma Pathway Inhibitors 有权人抗IFN-γ中和抗体作为选择性IFN-γ途径抑制剂公开(公告)号：US20140004127A1
公开(公告)日：2014-01-02
申请号：US13966185
申请日：2013-08-13
IPC分类号： C07K16/24
CPC分类号： C07K16/249 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76
摘要： This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-γ) and methods for treating IFN-γ mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-γ. Methods of detecting the amount of IFN-γ in a sample using antibodies to IFN-γ are also provided.
摘要翻译： 本发明提供了与人类干扰素-γ（IFN-γ）相互作用或与之结合的抗体以及通过向IFN-γ施用药学上有效量的抗体来治疗IFN-γ介导的疾病的方法。 还提供了使用针对IFN-γ的抗体检测样品中IFN-γ量的方法。
-
4.发明授权Methods for treating IFN-γ mediated diseases using human anti-IFN-γ neutralizing antibodies as selective IFN-gamma pathway inhibitors 有权使用人抗-γ-γ中和抗体作为选择性IFN-γ途径抑制剂治疗IFN-γ介导的疾病的方法公开(公告)号：US08529893B2
公开(公告)日：2013-09-10
申请号：US13476317
申请日：2012-05-21
IPC分类号： A61K39/395
CPC分类号： C07K16/249 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76
摘要： This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-γ) and methods for treating IFN-γ mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-γ. Methods of detecting the amount of IFN-γ in a sample using antibodies to IFN-γ are also provided.
摘要翻译： 本发明提供了与人类干扰素-γ（IFN-γ）相互作用或与之结合的抗体以及通过向IFN-γ施用药学上有效量的抗体来治疗IFN-γ介导的疾病的方法。 还提供了使用针对IFN-γ的抗体检测样品中IFN-γ量的方法。
-
5.发明授权Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitors 有权人抗IFN-γ中和抗体作为选择性IFN-γ途径抑制剂公开(公告)号：US07790859B2
公开(公告)日：2010-09-07
申请号：US11962594
申请日：2007-12-21
IPC分类号： A61K39/395 , C07K16/46
CPC分类号： C07K16/249 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76
摘要： This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-γ) and methods for treating IFN-γ mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-γ. Methods of detecting the amount of IFN-γ in a sample using antibodies to IFN-γ are also provided.
摘要翻译： 本发明提供了与人干扰素-γ（IFN-γ）相互作用或与之结合的抗体以及通过向IFN-γ施用药学上有效量的抗体来治疗IFN-γ介导的疾病的方法。 还提供了使用IFN-γ抗体检测样品中IFN-γ量的方法。
-
公开(公告)号：US08399647B2
公开(公告)日：2013-03-19
申请号：US13237502
申请日：2011-09-20
申请人： Steven L. Bender , Gerald F. Casperson , Dana D. Hu-Lowe , Xin Jiang , Gang Li , Michael A. North , Jianying Wang , Grant Wickman , Peter Brams , Haichun Huang , Brigitte Devaux , Haibin Chen , Dawn M. Tanamachi , Kristopher Toy , Lan Yang , Tim W. Sproul , Mark Yamanaka
发明人： Steven L. Bender , Gerald F. Casperson , Dana D. Hu-Lowe , Xin Jiang , Gang Li , Michael A. North , Jianying Wang , Grant Wickman , Peter Brams , Haichun Huang , Brigitte Devaux , Haibin Chen , Dawn M. Tanamachi , Kristopher Toy , Lan Yang , Tim W. Sproul , Mark Yamanaka
CPC分类号： C07K16/2842 , A61K2039/505 , C07K2317/21 , C07K2317/33 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/72 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2319/30
摘要： The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin α5β1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-α5β1 antibodies or antigen binding portions thereof described herein.
摘要翻译： 本公开提供以高亲和力特异性结合整联蛋白α5和bgr1的分离的单克隆抗体，特别是人单克隆抗体或其抗原结合部分。 还提供了编码本公开的抗体的核酸分子，表达载体，宿主细胞和用于表达本公开的抗体的方法。 还提供了免疫偶联物，双特异性分子和包含抗体或其抗原结合部分的药物组合物。 本公开还提供了使用本文所述的抗α5和bgr1抗体或其抗原结合部分治疗各种癌症的方法。
-
公开(公告)号：US08367063B2
公开(公告)日：2013-02-05
申请号：US12782376
申请日：2010-05-18
申请人： William J. Boyle , Eugene Medlock , John K. Sullivan , Robin L. Elliott , Frank Martin , Haichun Huang
发明人： William J. Boyle , Eugene Medlock , John K. Sullivan , Robin L. Elliott , Frank Martin , Haichun Huang
IPC分类号： A61K39/395 , A61K39/00 , C07K16/24 , C07K16/00
CPC分类号： C07K16/241 , A61K2039/505 , C07K16/2875 , C07K2317/21 , C07K2317/34 , C07K2317/56
摘要： Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.
-
公开(公告)号：US20120093826A1
公开(公告)日：2012-04-19
申请号：US13254752
申请日：2010-03-05
申请人： Jonathan Alexander Terrett , Heidi Leblanc , Haichun Huang , Erika Meaddough , Chin Pan , Bingliang Chen , Chetana Rao-Naik
发明人： Jonathan Alexander Terrett , Heidi Leblanc , Haichun Huang , Erika Meaddough , Chin Pan , Bingliang Chen , Chetana Rao-Naik
IPC分类号： A61K39/395 , C12N15/13 , C12N15/63 , A61P35/02 , C12P21/08 , C12N5/16 , A61P35/00 , C07K16/28 , C12N5/10
CPC分类号： C07K16/3007 , A61K33/24 , A61K39/39558 , A61K2039/505 , C07K16/3023 , C07K2317/24 , C07K2317/41 , C07K2317/73 , C07K2317/732 , C07K2317/77 , A61K2300/00
摘要： The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, more particularly engineered antibodies resulting in increased binding to Fc receptors and/or increased potency for ADCC or immunoconjugates, which specifically bind to CADM1 with high affinity. Nucleic acid molecules encoding CADM1 antibodies, expression vectors, host cells and methods for expressing the CADM1 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the CADM1 antibodies are also provided. Methods for detecting CADM1, as well as methods for treating various cancers, including lung cancer and pancreatic cancer, are disclosed.
摘要翻译： 本公开内容提供分离的单克隆抗体，特别是人单克隆抗体，更特别是工程化的抗体，其导致与Fc受体的增加的结合和/或增加对具有高亲和力特异性结合CADM1的ADCC或免疫偶联物的效力。 还提供编码CADM1抗体的核酸分子，表达载体，宿主细胞和用于表达CADM1抗体的方法。 还提供了包含CADM1抗体的双特异性分子和药物组合物。 公开了用于检测CADM1的方法，以及用于治疗各种癌症的方法，包括肺癌和胰腺癌。
-
公开(公告)号：US07960515B2
公开(公告)日：2011-06-14
申请号：US12332944
申请日：2008-12-11
申请人： Jing Min , Yanli Wu , Rory F. Finn , Barrett R. Thiele , Wei Liao , Ronald P. Gladue , Arvind Rajpal , Timothy J. Paradis , Peter Brams , Brigitte Devaux , Yi Wu , Kristopher Toy , Heidi N. LeBlanc , Haichun Huang
发明人： Jing Min , Yanli Wu , Rory F. Finn , Barrett R. Thiele , Wei Liao , Ronald P. Gladue , Arvind Rajpal , Timothy J. Paradis , Peter Brams , Brigitte Devaux , Yi Wu , Kristopher Toy , Heidi N. LeBlanc , Haichun Huang
IPC分类号： C07K16/00 , A61K39/395
CPC分类号： C07K16/2878 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/565 , C07K2317/92
摘要： The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.
摘要翻译： 本公开提供了结合人OX40R的分离的结合分子，编码结合分子的氨基酸序列的核酸分子，包含核酸分子的载体，含有载体的宿主细胞，制备结合分子的方法，含有 结合分子，以及使用结合分子或组合物的方法。
-
10.发明申请Human Anti-NGF Neutralizing Antibodies as Selective NGF Pathway Inhibitors 审中-公开人类抗NGF中和抗体作为选择性NGF途径抑制剂公开(公告)号：US20110091476A1
公开(公告)日：2011-04-21
申请号：US12880961
申请日：2010-09-13
申请人： Kenneth D. Wild, JR. , James J.S. Treanor , Haichun Huang , Heather Inoue , Tie J. Zhang , Frank Martin
发明人： Kenneth D. Wild, JR. , James J.S. Treanor , Haichun Huang , Heather Inoue , Tie J. Zhang , Frank Martin
IPC分类号： A61K39/395 , C12N5/10 , C12N15/63 , G01N33/566 , C07K16/22 , C07H21/04 , A61P19/02
CPC分类号： C07K16/22 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/51 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92 , G01N33/74 , G01N2333/48 , G01N2800/2842
摘要： This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
摘要翻译： 本发明提供与人神经生长因子（NGF）相互作用或结合的抗体，从而中和NGF的功能。 本发明还提供了所述抗体的药物组合物和中和NGF功能的方法，特别是通过施用药学上有效量的抗NGF抗体来治疗NGF相关疾病（例如慢性疼痛）。 还提供了使用抗NGF抗体检测样品中NGF量的方法。
-
-
-
-
-
-
-
-
-
搜索结果
75 条记录 (耗时 0.053 秒)
